Biopharmaceutical Company Cell Therapeutics, Inc. announced that its new drug pixantrone would be studied in a multicenter phase I/II trial for treating multiple sclerosis.
This is a (hopefully) improved version of Mitoxantrone, a drug already used in MS.
